News

Note: This story was updated May 26, 2026, to correct the time until symptom relief and the two formulations being investigated. Deucrictibant began relieving symptoms within a median of 1.28 hours. Developer Pharvaris is testing both immediate-release capsules and extended-release tablets. Pharvaris plans to soon submit an application to…

People with hereditary angioedema (HAE) who learn to accept and manage their disease, rather than constantly fighting or fearing it, often experience better mental well-being and a fuller, more active life, according to a survey study from the U.K. “Approaches aimed at fostering acceptance may offer a valuable means…

Patients with hereditary angioedema (HAE) should ideally receive on-demand treatment within one hour of their first symptoms, according to an international panel of 19 specialists. However, the experts warned that several obstacles, ranging from the difficulty in recognizing early symptoms to the physical burden of using needles, often…

Biocryst Pharmaceuticals is once again partnering with Neopharmed Gentili — now, with an Irish affiliate of the Italian pharmaceutical company — this time for marketing rights in Europe to navenibart, the still-experimental treatment Biocryst is developing to prevent attacks of hereditary angioedema (HAE) Under the terms of a new…

Chiesi has entered into a definitive agreement to acquire Kalvista Pharmaceuticals, and with it, Ekterly (sebetralstat), an oral on‑demand treatment for acute swelling attacks in people with hereditary angioedema (HAE). The transaction was approved by both companies’ boards of directors and is expected to be completed by the…

A single dose of lonvoguran ziclumeran (lonvo-z) left more than 60% of patients with hereditary angioedema (HAE) free of swelling attacks and ongoing therapy during a six-month evaluation period, suggesting it could reduce the need for lifelong preventive therapy if approved. That is according to topline data from…

Advocates around the world are preparing to mark May 16 as the day of awareness for hereditary angioedema (HAE), a rare genetic disorder that still takes an average of eight years to diagnose. Since its inception in 2012, the annual observance known as “hae day :-)” has evolved…

On May 16, organizations and supporters worldwide will mark hae day : -) — designed to raise awareness of hereditary angioedema (HAE) — through a range of activities, from a foot race around the bridges of Osijek, Croatia, to the illumination of landmarks throughout Canada. The annual event…

Using a daily extended-release tablet of deucrictibant — an oral small molecule being developed by Pharvaris — together with deucrictibant in its immediate-release formulation as an on-demand treatment for acute attacks of hereditary angioedema (HAE) is expected to be safe based on computer data. A presentation on…

The experimental therapy navenibart was well tolerated and was associated with fewer swelling attacks and improved quality of life in adults with hereditary angioedema (HAE) when given every few months in an early clinical trial, a study showed. “The proof-of-concept data … suggest that infrequent administration of navenibart…